Trial
NCT04049617
Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Efficacy of Evixapodlin (Formerly GS-4224) in Participants With Advanced Solid Tumors
Phase ITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Gilead Sciences
Collaborators
—
Condition
Advanced Solid Tumors
Intervention
Evixapodlin
Why stopped
Gilead decision to terminate
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2022-10-06